IN8BIO, INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
INAB$0.94+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(In thousands)
| Year EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(19,440) | $(30,437) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,000 | 976 |
| Non-cash stock-based compensation | 3,189 | 5,000 |
| Amortization of finance lease right-of-use assets | 771 | 859 |
| Amortization of operating lease right-of-use assets | 730 | 820 |
| Loss on disposal of construction in progress | — | 45 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 670 | 1,889 |
| Other non-current assets | 129 | (20) |
| Accounts payable | (80) | (535) |
| Accrued expenses and other current liabilities | 586 | (1,908) |
| Short-term operating lease liabilities | 612 | 134 |
| Long-term operating lease liabilities | (879) | (972) |
| Net cash used in operating activities | (12,712) | (24,149) |
| Investing activities | ||
| Purchases of property and equipment | — | (104) |
| Construction in progress | — | (83) |
| Net cash used in investing activities | — | (187) |
| Financing activities | ||
| Payment of issuance costs from December 2023 issuance of common stock | — | (89) |
| Proceeds from the issuance of common stock, net of issuance costs | 8,566 | 3,816 |
| Proceeds from the exercise of Series A, B and C warrants, net of issuance costs | 2,264 | 25 |
| Proceeds from private placement common stock, net of issuance costs | 18,501 | 6,127 |
| Proceeds from private placement warrants, net of issuance costs | — | 5,099 |
| Principal payments on finance leases | (693) | (794) |
| Net cash provided by financing activities | 28,638 | 14,184 |
| Net increase (decrease) in cash and restricted cash | 15,926 | (10,152) |
| Cash and restricted cash at beginning of year | 11,386 | 21,538 |
| Cash and restricted cash at end of year | $27,312 | $11,386 |
| Supplemental disclosure of non-cash operating, financing and investing information: | ||
| Initial measurement of operating lease right-of-use assets and liabilities | $— | $714 |
| Initial measurement of finance lease right-of-use assets and liabilities | $— | $564 |
| Lease modification of operating lease right-of-use assets and liabilities | $(1,287) | $492 |
| Lease modification of finance lease right-of-use assets and liabilities | $(1) | $— |
| Transfer of construction in progress to property and equipment | $— | $221 |
Statements of Cash Flows Continued
(In thousands)
The following table provides a reconciliation of cash and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows:
| Year EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash, end of year | $27,092 | $11,120 |
| Restricted cash, end of year | 220 | 266 |
| Cash and restricted cash, end of year | $27,312 | $11,386 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.